Attachment H CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICEO F INSPECTOGRE NERAL OF THE DEPARTMENOTF HEALTHA ND HUMANS ERVICES AND K ~ NPGH ARMACEUTICAILNSC, . King Pharmaceuticals, Inc., and its United States subsidiaries that manufacture or sell pharmaceutical products (collectively, "King") hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. 5 1320a-7b(f)) in which King participates and the requirements of other government programs in which King participates (collectively, "Federal Health Care Programs") specified below in Section II.C.2 (Federal Health Care Program Requirements). Contemporaneously with this CIA, King is entering into a settlement agreement with the United States (Settlement Agreement), and this CIA is incorporated by reference into the Settlement Agreement. King also will enter into settlement agreements with various States, and King's agreement to this CIA is a condition precedent to those agreements. Prior to the Effective Date of this CIA (as defined below), King established a voluntary compliance program which, as represented by King, includes, among other things, the appointment of a Corporate Compliance Officer, the development and dissemination of a Code of Conduct, the establishment of written policies and procedures, a Disclosure Program, screening measures for Ineligible Persons, review and disciplinary proceedings, regular training to Covered Persons concerning King's Code of Conduct and policies and procedures, and regular internal auditing. Corporate Integrity Agreement King Pharmaceuticals, Inc.